Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers
Maria Empar Blanco-Cantó1, J A Monge-Argilés1, C Pérez-Cejuela2
11 Department of Neurology, General University Hospital of Alicante, Alicante, Spain.
American Journal of Alzheimer'S Disease and Other Dementias
|February 14, 2017
Summary
New criteria using cerebrospinal fluid (CSF) biomarker ratios showed higher diagnostic validity for Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) compared to existing NIA-AA standards.
Area of Science:
- Neurology
- Biomarker Research
- Neurodegenerative Diseases
Background:
- Mild Cognitive Impairment (MCI) is a prodromal stage for Alzheimer's disease (AD).
- Accurate diagnosis of MCI due to AD is crucial for timely intervention.
- Cerebrospinal fluid (CSF) biomarkers are increasingly used in AD diagnosis.
Purpose of the Study:
- To evaluate the diagnostic accuracy of novel criteria for AD CSF biomarkers.
- To compare these new criteria against the established NIA-AA criteria.
Main Methods:
- 170 MCI patients were analyzed for CSF Aβ1-42, T-tau, P-tau181, and biomarker ratios.
- New criteria considered 3 or more abnormal variables, including ratios, for MCI due to AD diagnosis.
- Diagnostic validity, specificity, PPV, and NPV were calculated for both criteria sets.
Main Results:
- The novel criteria demonstrated a diagnostic validity of 85% compared to 58% for NIA-AA criteria.
- Specificity was 72% for new criteria versus 84% for NIA-AA.
- Positive Predictive Value (PPV) was 79% (new) vs. 82% (NIA-AA), and Negative Predictive Value (NPV) was 79% (new) vs. 61% (NIA-AA).
Conclusions:
- Incorporating CSF biomarker ratios into diagnostic criteria significantly enhances sensitivity and NPV for MCI due to AD.
- The proposed criteria offer improved diagnostic performance for identifying MCI attributable to Alzheimer's disease.
